Patents by Inventor Michel Adam

Michel Adam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250109166
    Abstract: The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof, wherein PG1, PG2 and PG3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.
    Type: Application
    Filed: August 13, 2024
    Publication date: April 3, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Fritz Bliss, Pascal Jean Claude Dott, Fabienne Roxane Hoffmann-Emery, Ulf Göran Larsson, Kurt Puentener
  • Publication number: 20250084102
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: August 7, 2024
    Publication date: March 13, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel ADAM, Serena Maria FANTASIA, Daniel Vincent FISHLOCK, Fabienne HOFFMANN-EMERY, Gerard MOINE, Christophe PFLEGER, Christian MOESSNER
  • Patent number: 12227535
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 19, 2022
    Date of Patent: February 18, 2025
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Patent number: 12122791
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: October 22, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Publication number: 20240324729
    Abstract: An apparatus for stretching footwear, wherein an inflatable bladder is inserted into the footwear at a desired location as determined by the user. The various embodiments of the apparatus allow for various areas of the footwear, including the instep, the vamp, the calf area or shaft, and other areas of the footwear to be uniformly expanded without causing damage to the footwear. In one embodiment, a bladder having a rounded peak is inserted into the toe-box of the footwear and inflated to a desired pressure. Alternatively, other embodiments may be inserted into the calf section of a footwear such as a boot to expand the material around the leg and calf of a user. An air valve allows for users to inflate the apparatus while said apparatus is inside of the footwear.
    Type: Application
    Filed: March 30, 2023
    Publication date: October 3, 2024
    Inventor: Michelle Adams
  • Publication number: 20240309013
    Abstract: The invention provides crystalline forms of 2?-(7,7-dimethyl-1?H,7H-spiro[furo[3,4-b]pyridine-5,4?-piperidin]-1?-yl)-1,3-dihydro-4?H-spiro[indene-2,5?-[1,3]oxazol]-4?-one, and a process for converting Form A to Form B for use in medicaments for treatment of anxiety, depression, irritability, impaired social interactions and psychomotor coordination, and other indications. The invention further provides processes to manufacture 2?-(7,7-dimethyl-1?H,7H-spiro[furo[3,4-b]pyridine-5,4?-piperidin]-1?-yl)-1,3-dihydro-4?H-spiro[indene-2,5?-[1,3]oxazol]-4?-one. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Application
    Filed: May 16, 2024
    Publication date: September 19, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel ADAM, Stephan BACHMANN, Raphael BIGLER, Pascal DOTT, Serena Maria FANTASIA, Katja GROSSE-SENDER, Philippe JAMES, Paul SPURR, Juergen THUN, Sandro TONAZZI, Paolo TOSATTI
  • Publication number: 20240287084
    Abstract: The present invention relates to a process for the preparation of [1,2,3]triazolo[4,5-d]pyrimidine derivatives useful as pharmaceutically active compounds, in particular 1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol.
    Type: Application
    Filed: April 24, 2024
    Publication date: August 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Uwe Grether, Christian Moessner, Paolo Tosatti
  • Publication number: 20240182493
    Abstract: The present invention relates to a process for the preparation of 7-(4.7-diazaspiro[2.5]octan-7-vl)-2-(2.8-dimethylimidazo[1.2-b]pyridazin-6-vl)pyrido[1.2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: September 15, 2023
    Publication date: June 6, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel ADAM, Christophe Pfleger, Georg Wuitschik
  • Patent number: 11925653
    Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: March 12, 2024
    Assignee: FLEURIR ABX, LLC
    Inventors: John Lee Pace, Marc Edwin Wiles, Stacy Michelle Adams, Elizabeth Hussey
  • Publication number: 20220324881
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfeger, Christian Moessner
  • Patent number: 11447515
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 20, 2022
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Patent number: 11390632
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Publication number: 20210284648
    Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 16, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benno Rothenhaeusler, Rene Trussardi, Fabienne Hoffmann-Emery, Urs Schwitter, Jean-Michel Adam, Olaf Grassmann, Thomas Hartung, Frederic Ran, Ralph Diodone, Christophe Pfleger, Bjorn Bartels
  • Patent number: 11040977
    Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: June 22, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benno Rothenhaeusler, Rene Trussardi, Fabienne Hoffmann-Emery, Urs Schwitter, Jean-Michel Adam, Olaf Grassmann, Thomas Hartung, Frederic Ran, Ralph Diodone, Christophe Pfleger, Bjorn Bartels
  • Patent number: 10898501
    Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: January 26, 2021
    Assignee: FLEURIR ABX, LLC
    Inventors: John Lee Pace, Marc Edwin Wiles, Stacy Michelle Adams, Elizabeth Hussey
  • Publication number: 20200216472
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Publication number: 20190315669
    Abstract: The invention provides processes for the preparation of HU-910, which are scalable to industrial purposes, using safer reagents and having high yield and pure product and a crystalline structure of HU-910, which is a unique product thereof.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 17, 2019
    Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
    Inventors: Jean-Michel ADAM, Pascal DOTT, Marcus HOHLER, Tanja BURGER, Orazio TAGLIENTE, Ernst MISCHLER
  • Publication number: 20190194210
    Abstract: The invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benno Rothenhaeusler, Rene Trussardi, Fabienne Hoffmann-Emery, Urs Schwitter, Jean-Michel Adam, Olaf Grassmann, Thomas Hartung, Frederic Ran, Ralph Diodone, Christophe Pfleger, Bjorn Bartels
  • Patent number: 10246460
    Abstract: The present invention provides processes to manufacture substituted 1-[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes. Also disclosed are compounds useful as intermediates in the methods of the invention.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 2, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Benno Rothenhaeusler, Rene Trussardi, Fabienne Hoffmann-Emery, Urs Schwitter, Jean-Michel Adam, Olaf Grassmann, Thomas Hartung, Frederic Ran, Ralph Diodone, Christophe Pfleger, Bjorn Bartels
  • Patent number: 9718850
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 1, 2017
    Assignee: MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan